NQ301

NQ301 (CAS No.: 130089-98-4) is a small-molecule antithrombotic agent widely used in biomedical research to investigate platelet activation and thromboxane-mediated signaling pathways. It exerts its pharmacological effects primarily through dual inhibition of thromboxane A2 receptor activity and thromboxane A2 synthase, thereby attenuating thromboxane A2/prostaglandin H2 signaling and modulating arachidonic acid metabolism, including the regulation of 12-hydroxyeicosatetraenoic acid formation. In vitro, NQ301 inhibits collagen-induced aggregation of washed rabbit platelets in a concentration-dependent manner, with activity observed at milligram-per-milliliter levels, and suppresses human platelet aggregation triggered by multiple agonists, including collagen, thrombin, arachidonic acid, thapsigargin, and calcium ionophore A23187, with inhibitory effects spanning low to mid micromolar ranges depending on the stimulus. Mechanistically, its antiplatelet activity is associated with interference in intracellular calcium mobilization, a critical step in platelet activation and granule secretion. NQ301 is therefore a useful tool compound for studying platelet physiology, thrombotic disease mechanisms, and eicosanoid signaling, and is commonly applied in cell-based assays and preclinical models where experimental concentrations are adjusted according to specific study designs and endpoints.